Improved time to treatment failure with an intermittent oxaliplatin strategy: results of CONcePT.

ABSTRACT:

Background

Oxaliplatin is an integral component of colorectal cancer treatment, but its use is limited by neurotoxicity. The Combined Oxaliplatin Neurotoxicity Prevention Trial (CONcePT) tested intermittent oxaliplatin (IO) administration and the use of concurrent calcium and magnesium salts (Ca/Mg), two modifications intended to reduce neurotoxicity and extend the duration of treatment.

Patients and methods

In this trial involving double randomization, 140 patients were randomized to receive modified FOLFOX7 plus bevacizumab with IO (eight-cycle blocks of oxaliplatin treatment) versus continuous oxaliplatin (CO); and Ca/Mg versus placebo (pre- and postoxaliplatin infusion). The primary end point was time-to-treatment failure (TTF).

Results

One hundred thirty-nine pat

SUBMITTER: Hochster HS 

PROVIDER: S-EPMC4207881 | biostudies-literature | 2014 Jun

REPOSITORIES: biostudies-literature